Search
- Aug 1, 2023
Exclusive: Pfizer’s CEO on Q2 earnings
Albert Bourla discusses Q2 earnings, the Seagen deal, Pfizer’s capacity for more deals, GLP-1s, and an update on the NC tornado damage.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A